fda approves lilly pill for common advanced breast cancer

Eli Lilly's Verzenio was approved Thursday by the Food and Drug Administration for women and men with what's called HR-positive, HER2-negative breast cancer that has worsened after hormone therapy. According to the FDA, about 72 percent of patients with breast cancer have this type. The daily pill blocks certain enzymes that promote growth of cancer...